Position in LYEL
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$29,448
-$20,292 QoQ
Shares Held
1,468
-9.2% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026JPMORGAN CHASE & CO holds $16,579,226,864 across 407 Biotechnology names. LYEL ranks #274 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
24,150,499 | $3,949,089,591 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,311,806 | $3,331,473,778 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,033,156 | $3,140,585,469 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
6,323,752 | $2,092,339,815 | |
| 5 | NUVL |
Nuvalent, Inc.
|
3,088,349 | $316,401,351 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,204,353 | $227,682,931 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
2,363,567 | $177,480,242 | |
| 8 | TERN |
Terns Pharmaceuticals, Inc.
|
2,869,728 | $151,292,056 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,448 | 1,468 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $49,740 | 1,616 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $7,957 | 490 | Shares | Defined | 2025-11-26 | |
| 2025-06-30 | $29,781 | 3,369 | Shares | Defined | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||